Natco Pharma: Alvogen to market generic equivalent to oseltamivir phosphate in USA

Natco's marketing partner Alvogen first to market generic equivalent to oseltamivir phosphate powder for oral suspension in the USA.

November 03, 2017 / 11:19 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Natco's marketing partner Alvogen first to market generic equivalent to oseltamivir phosphate powder for oral suspension in the USA

Natco Pharma’s marketing partner Alvogen has received the final approval and it is first to market the generic equivalent to oseltamivir phosphate, 6mg/ml powder for oral suspension in the United States.

At 11:11 hrs Natco Pharma was quoting at Rs 970.10, down Rs 26.60, or 2.67 percent.Source : BSE

first published: Nov 3, 2017 11:19 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347